Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity - Related Studies

Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity

This study has been completed.

Study NCT00001577. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Melanoma
		Sarcoma

2	More general conditions related to this trial
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Connective and Soft Tissue
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Nevi and Melanomas

3	Additional drug interventions recognized in this trial
		Melphalan

4	More general drug interventions related to this trial
		Alkylating Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

5	Sponsors listed in this trial
		National Cancer Institute (NCI)